A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <i>EGFR</i> -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Kazuhiko Nakagawa, Yasushi Fukuda et al.|Clinical Cancer Research|2021Cited by 76